CYP51/HDAC-IN-1

CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis[1].

Product Specifications

CAS Number

[2502095-64-7]

UNSPSC

12352005

Target

Cytochrome P450; Fungal; HDAC

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cyp51-hdac-in-1.html

Solubility

10 mM in DMSO

Smiles

O=C(CCCCCCCOC1=CC=C(CN2CCN(CC(C3=CC=C(C=C3F)F)(CN4N=CN=C4)O)CC2)C=C1)NO

Molecular Formula

C30H40F2N6O4

Molecular Weight

586.67

References & Citations

[1]Zhu T, et al. Lanosterol 14α-demethylase (CYP51) /histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. Eur J Med Chem. 2021. 221:113524.